Bayer AG Stock Under Pressure as Activist Investor Inclusive Capital Exits Position Amid Ongoing US Litigation Risks

The Bayer AG stock (ISIN: DE000BAY0017) faced sharp selling pressure on Xetra after activist investor Inclusive Capital sold its remaining 8.5 million shares at a discount, highlighting persistent challenges from Roundup litigation and uncertain Supreme Court proceedings. US investors should monitor this closely due to Bayer's heavy exposure to American legal risks and pharmaceutical opportunities.

The Bayer AG stock dropped significantly on Xetra, closing at 37.74 euros on March 24, 2026, down 1.88% amid the exit of activist investor Inclusive Capital Partners. This sale of 8.5 million shares at 37.45 euros per share, a 2.6% discount to the prior close, raised 318 million euros and signaled waning confidence from a key shareholder who had pushed for management changes. For US investors, this development underscores Bayer's vulnerability to US-specific litigation over Roundup, even as the company advances in pharmaceuticals like Eylea in Japan.

As of: 25.03.2026

Dr. Elena Voss, Pharma Sector Analyst: Bayer's dual exposure to agriculture litigation and innovative pharma pipelines makes its stock a high-stakes play for US investors navigating global health sector shifts.

Activist Investor Exit Triggers Immediate Selloff

Inclusive Capital Partners, led by Jeff Ubben, completed the sale of its entire remaining stake in Bayer AG overnight into March 24, 2026. The firm offloaded 8.5 million shares, equivalent to about 0.9% of the company's capital, at 37.45 euros per share on Xetra. This priced the accelerated bookbuild offering at a discount to Monday's closing price of 38.47 euros, contributing to a session low of around 37.05 euros early in trading.

The move erased recent gains, with the Bayer AG stock down as much as 3.7% intraday before closing at 37.74 euros on Xetra. Volume spiked to over 3 million shares, reflecting heightened trader interest. Inclusive Capital had entered Bayer in early 2023, advocating for an external CEO hire, but appears to have booked a loss on the position amid prolonged underperformance.

This exit removes a vocal activist voice that had pressured Bayer on strategic spin-offs and cost cuts. Market reaction was swift, positioning Bayer among the weakest performers on the DAX index that day. The sale's timing, just before the US Supreme Court prepares to hear a pivotal Roundup case, amplifies concerns over unresolved liabilities.

Persistent Roundup Litigation Shadows Bayer's Valuation

Bayer's acquisition of Monsanto in 2018 brought a torrent of US lawsuits alleging Roundup causes cancer, with over 170,000 claims settled or pending. The company has reserved billions for resolutions, but ongoing cases continue to erode investor confidence. Shares have lost about 25% since peaks, trading at a market cap of roughly 37.79 billion euros with 982.42 million shares outstanding.

Valuation metrics reflect distress: a negative P/E ratio due to recent losses, KBV of 1.40, and KCV of 7.95. Volatility remains high at 44.18% over 30 days. Analyst consensus leans to Outperform with a 46.74 euro target, implying 21.5% upside from recent levels, but negative sentiment persists since early February 2026.

Efforts to mitigate include state-level shield laws, successful in Georgia but failing elsewhere. These aim to block certain lawsuits, but federal clarity hinges on judicial outcomes. Bayer's pharma division provides offset, yet agriculture woes dominate headlines.

US Supreme Court Case Looms as Key Catalyst

The US Supreme Court is set to hear a landmark Roundup case in the second half of June 2026, potentially reshaping Bayer's legal exposure. A favorable ruling could dismantle the basis for many remaining suits, unlocking value in the Crop Science division. Bayer closed the prior week at 38.50 euros on Xetra, down 4.11% weekly.

Management views this as pivotal for long-term stability. Parallel state protections offer partial relief, but national uniformity is needed. Pharma growth, with 2026 net income forecasts around 1.92 billion euros rising to 3.03 billion in 2027, provides a buffer. EV/Sales multiples stand at 1.53x for 2026, tightening to 1.42x next year.

Recent analyst upgrades, like Oddo BHF to Outperform on March 20, highlight pipeline strength. Yet, the litigation overhang caps multiples compared to pure-play pharma peers.

Pharma Wins in Japan Bolster Diversification Case

Bayer secured key regulatory approvals in Japan on March 23, 2026, for Eylea 8mg in a third retinal indication and Ambelvist, a new MRI contrast agent. These expand addressable markets in ophthalmology and diagnostics, key pharma growth drivers. Eylea, a blockbuster vascular endothelial growth factor inhibitor, sees higher-dose efficacy boosting competitiveness.

Japan represents a stable, high-margin market less exposed to US litigation noise. Approvals validate Bayer's R&D execution post-Monsanto, with PER forecasts improving to 12.3x by 2027. Dividend yield projections of 0.59% in 2026 rising to 2% signal return potential if risks abate.

These milestones contrast agriculture pressures, reinforcing arguments for segment separation long pushed by activists like Inclusive Capital.

Why US Investors Should Watch Bayer Closely Now

US investors hold significant Bayer exposure via ADRs and funds, with litigation centered in American courts. A Supreme Court win could trigger re-rating, given the stock's 56% one-year gain before recent pullback. Crop Science contributes over 40% of sales but carries disproportionate risk from US verdicts.

Pharma stability appeals to dividend seekers, with free float at 100% ensuring liquidity. Compared to US peers like Eli Lilly or Pfizer, Bayer trades at a discount on forward earnings, offering asymmetry if legal clouds lift. Tariff risks on ag products add layers, but Japan wins diversify revenue.

Macro tailwinds in global health spending favor Bayer's portfolio. US portfolios diversified into European pharma gain from currency hedges and undervaluation.

Risks and Open Questions Ahead

Supreme Court loss could swell liabilities beyond current reserves, pressuring balance sheets. Activist exit may invite others, renewing spin-off debates. High volatility (43.83% over 180 days) suits not all risk tolerances.

Relative performance lags STOXX 600 by 3.04% over four weeks, with negative technical trends since early March. Chemical industry bargaining adds wage cost risks. US policy shifts post-elections could impact shield laws.

Despite analyst buy ratings from Barclays and Goldman Sachs on March 16, high risk classification since February 20 persists. Investors must weigh pharma upside against ag downside.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.